Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
Baxter
Mallinckrodt
Medtronic

Last Updated: May 25, 2022

Investigational Drug Information for Reparixin


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Reparixin?

Reparixin is an investigational drug.

There have been 12 clinical trials for Reparixin. The most recent clinical trial was a Phase 3 trial, which was initiated on February 14th 2021.

The most common disease conditions in clinical trials are Breast Neoplasms, Pneumonia, and COVID-19. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and [disabled in preview].

There are ninety-one US patents protecting this investigational drug and nine hundred and thirty-nine international patents.

Recent Clinical Trials for Reparixin
TitleSponsorPhase
Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19.Dompé Farmaceutici S.p.APhase 3
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast CancerDompé Farmaceutici S.p.APhase 2
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.Dompé Farmaceutici S.p.APhase 3

See all Reparixin clinical trials

Clinical Trial Summary for Reparixin

Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin

See all Reparixin clinical trials

US Patents for Reparixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Reparixin See Plans and Pricing Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) See Plans and Pricing
Reparixin See Plans and Pricing Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) See Plans and Pricing
Reparixin See Plans and Pricing Combination therapy DIMERIX BIOSCIENCE PTY LTD. (Victoria, AU) See Plans and Pricing
Reparixin See Plans and Pricing Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) See Plans and Pricing
Reparixin See Plans and Pricing Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) See Plans and Pricing
Reparixin See Plans and Pricing Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Reparixin

Drugname Country Document Number Estimated Expiration Related US Patent
Reparixin Canada CA2961033 2034-09-11 See Plans and Pricing
Reparixin European Patent Office EP3192791 2034-09-11 See Plans and Pricing
Reparixin Japan JPWO2016039408 2034-09-11 See Plans and Pricing
Reparixin World Intellectual Property Organization (WIPO) WO2016039408 2034-09-11 See Plans and Pricing
Reparixin Argentina AR098909 2033-07-03 See Plans and Pricing
Reparixin European Patent Office EP3018126 2033-07-03 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
Baxter
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.